November 18, 2026
Breaking
Business

Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment

admin1 min read

The approval makes Biocon’s pertuzumab the first biosimilar to receive EC marketing authorisation under the European Medicines Agency’s (EMA) new tailored clinical approach

The post Biocon's Pebrilzo gets EU nod for HER2-positive breast cancer treatment appeared first on Home Page.

Leave a Comment

Your email address will not be published. Required fields are marked *